Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model release_ztgv4at5cnfubaxoynom566hmi

by Clara Correa-Paz, María F. Navarro Poupard, Ester Polo, Manuel Rodríguez-Pérez, Martina Migliavacca, Ramón Iglesias-Rey, Alberto Ouro, Elena Maqueda, Pablo Hervella, Tomás Sobrino, José Castillo, Pablo del Pino (+2 others)

Published in Journal of Nanobiotechnology by Springer Science and Business Media LLC.

2022   Volume 20, Issue 1, p46

Abstract

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> Ischemic stroke is the most common cerebrovascular disease and is caused by interruption of blood supply to the brain. To date, recombinant tissue plasminogen activator (rtPA) has been the main pharmacological treatment in the acute phase. However, this treatment has some drawbacks, such as a short half-life, low reperfusion rate, risk of hemorrhagic transformations, and neurotoxic effects. To overcome the limitations of rtPA and improve its effectiveness, we recently designed sonosensitive sub-micrometric capsules (SCs) loaded with rtPA with a size of approximately 600 nm, synthesized using the layer-by-layer (LbL) technique, and coated with gelatine for clot targeting. In this study, we evaluated the rtPA release of ultrasound (US)-responsive SCs in healthy mice and the therapeutic effect in a thromboembolic stroke model. </jats:sec><jats:sec> <jats:title>Results</jats:title> In healthy mice, SCs loaded with rtPA 1 mg/kg responded properly to external US exposure, extending the half-life of the drug in the blood stream more than the group treated with free rtPA solution. The gelatine coating also contributed to stabilizing the encapsulation and maintaining the response to US. When the same particles were administered in the stroke model, these SCs appeared to aggregate in the ischemic brain region, probably generating secondary embolisms and limiting the thrombolytic effect of rtPA. Despite the promising results of these thrombolytic particles, at least under the dose and size conditions used in this study, the administration of these capsules represents a risk factor for stroke. </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> This is the first study to report the aggregation risk of a drug carrier in neurological pathologies such as stroke. Biocompatibility analysis related to the use of nano-and microparticles should be deeply studied to anticipate the limitations and orientate the design of new nanoparticles for translation to humans. </jats:sec><jats:sec> <jats:title>Graphical Abstract</jats:title> </jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  3.1 MB
file_rfrvbijoqvhiffut6rlre5uhia
jnanobiotechnology.biomedcentral.com (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-01-21
Language   en ?
Journal Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  1477-3155
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 93541607-fab4-461b-9b8b-60e9cb835602
API URL: JSON